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Abstract. Background: Gemcitabine (GEM) plus cisplatin
(CDDP) chemotherapy has been used worldwide as the
standard first-line treatment for advanced biliary tract
cancer (BTC). A phase II trial has also suggested promising
activity of GEM plus S-1 chemotherapy against advanced
BTC. The aim of this study was to evaluate the efficacy and
safety of GEM plus S-1 chemotherapy in patients with
advanced BTC. Patients and Methods: The eligibility criteria
were as follows: histologically-proven BTC, unresectable or
recurrent disease, ECOG performance status (PS) 0-1
regardless of previous treatment. Gemcitabine was
administered intravenously at the dose of 1,000 mg/m2 over
30 min on days 1 and 8, and S-1 was administered orally at
doses of 60/80/100 mg/day based on the BSA, from day 1 to
day 14, every 3 weeks. The primary endpoint was the
response rate according to RECIST, ver. 1.1, and the
secondary endpoints were the frequency/severity of toxicities,
progression-free survival (PFS) and overall survival (OS).
Results: A total of 38 patients were enrolled between August
2008 and November 2011. There were 19 men and 19
women, with a median age of 66 years (range=44-81 years).
Seven patients had a previous history of first-line or adjuvant
chemotherapy after surgery. The PS was 0 and 1 in 30 and
7 patients, respectively. The treatment response was
classified as partial response in 6 patients (15.8%) and as
stable disease in 18 patients (47.4%). The median PFS and
OS were 5.8 and 15.9 months, respectively. The toxicity was
generally mild, and the most common grade 3/4 toxicities
were leukopenia (31.6%), neutropenia (36.8%),
nausea/vomiting (2.6%), and diarrhea (2.6%). There was
one treatment-related death due to interstitial pneumonia.
Conclusion: Our study revealed that gemcitabine plus S-1
chemotherapy was well-tolerated and exhibited favorable
antitumor activity in patients with advanced BTC.
Biliary tract cancer comprises extrahepatic cholangiocarcinoma
(EHCC), gallbladder cancer (GBC) and ampulla of Vater
cancer (AVC); intrahepatic cholangiocarcinoma (IHCC) is also
often included in clinical trials of treatments for biliary tract
cancer. The incidence is high in Asia and south America and
approximately 25,000 patients are annually diagnosed as
having biliary tract cancer in Japan (1). While BTC is
recognized as a relatively rare disease in Western countries, the
incidence of intrahepatic cholangiocarcinoma is gradually
increasing in Western countries (2-6). 
Biliary tract cancer is a common cause of cancer-related
death in Asia, including Japan, with an estimated 18,000
deaths occurring from this cancer annually in Japan. While
surgery currently remains the only potentially curative
treatment, many patients are diagnosed at an advanced,
unresectable stage of the disease. Even among patients with
advanced disease who are treated by curative surgery, disease
recurrence occurs at a high frequency (7). Thus, although
systemic chemotherapy plays an important role in the
treatment of advanced biliary tract cancer, the prognosis of
this cancer remains extremely poor.
In the ABC-02 trial, a randomized phase III study carried
out in the U.K. to compare gemcitabine alone with
gemcitabine plus cisplatin (GC) in patients with unresectable
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or recurrent biliary tract cancer, a statistically significantly
higher overall survival rate was obtained in the GC arm as
compared to the gemcitabine-alone arm (8). In the BT22
study, a randomized controlled trial carried out to confirm
the efficacy/safety of GC therapy as compared to that of
gemcitabine monotherapy in Japanese patients, similar
results to those of the ABC-02 study were obtained (9).
Thus, GC therapy is now recognized as the global standard
for chemotherapy of unresectable biliary tract cancer.
On the other hand, S-1 is an oral anticancer drug that
consists of a mixture of tegafur (FT), 5-chloro-2,4-
dihydroxypyridine (CDHP), and potassium oxonate (Oxo);
FT is a prodrug of 5-FU, CDHP is a competitive inhibitor of
dihydropyrimidine dehydrogenase (DPD), an enzyme that
catalyzes the degradation of 5-FU, and oxo is a competitive
inhibitor of orotate phosphoribosyltransferase (OPRT) and
inhibits the phosphorylation of 5-FU in the gastrointestinal
tract, reducing the serious gastrointestinal toxicity of 5-FU.
A phase II study of S-1 for advanced biliary tract cancer
demonstrated promising activity, with a response rate of
35%, median time-to-progression of 3.7 months, and median
overall survival of 9.4 months (10). Based on these results,
S-1 was approved for the treatment of biliary tract cancer in
Japan in 2007.
Furthermore, combination of gemcitabine and S-1 has also
been demonstrated to show promising activity against biliary
tract cancer and pancreatic cancer (11-13). Therefore, we
conducted this multicenter phase II study to evaluate the
efficacy and safety of gemcitabine plus S-1 chemotherapy
(GS therapy) in patients with unresectable biliary tract
cancer. 
Patients and Methods
Patient eligibility. The eligibility criteria of patients for enrollment in
the phase II study were: histologically or cytologically confirmed
adenocarcinoma or adenosquamous carcinoma; clinical diagnosis of
biliary tract cancer (IHCC, EHCC, GBC or AVC); measurable disease
on computed tomography (CT) or magnetic resonance imaging (MRI)
unresectable disease; age ≥20 years old; Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0-1; capable of
sufficient oral intake; preserved organ functions (leukocyte count
3,500/mm3 or more, neutrophil count 1,500/mm3 or more, platelet
count 100,000/mm3 or more, hemoglobin level 9 g/100 mL or more,
serum creatinine concentration 1.2 mg/dL or less, serum total
bilirubin level 2 mg/dL or less (3 mg/dL or less in patients with
biliary drainage) and serum aspartate transaminase (AST) and alanine
transaminase (ALT) levels 150 IU/L or less; life expectancy ≥8
weeks; willing to provide written informed consent. The exclusion
criteria were: serious complications such as active infection, active
gastrointestinal ulcer, cardiac disease, and/or renal disease; central
nervous system metastasis; massive pleural effusion or ascites;
symptomatic interstitial pneumonitis; pregnant or lactating women.
In this study, patients with a previous history of chemotherapy were
not excluded, because we expected that GS therapy would be
efficacious as a second-line treatment as well. This study was
conducted with the approval of the local institutional review boards
of all the participating centers (approval number: 20-2).
Treatment methods. The dose and dosing schedule of GS therapy
were as follows; 1000 mg/m2 of gemcitabine was administered by
intravenous infusion on days 1 and 8, and S-1 at 30 mg/m2
(60 mg/day for a body surface area [BSA] <1.25 m2, 80 mg/day for
1.25 ≤ BSA <1.50 m2, and 100 mg/day for BSA ≥1.50 m2) was
administered orally twice daily from days 1 to 14, repeated every 3
weeks. The treatment cycles were repeated until documentation of
disease progression, emergence of unacceptable toxicity or patient
refusal to continue the treatment. Prophylactic administration of
antiemetic agents such as dexamethasone and/or a 5-HT3 receptor
antagonist was allowed at the investigator’s discretion. 
If a patient’s leukocyte count was <3,000/mm3, platelet count
was <100,000/mm3, total bilirubin level was >3.0 mg/dL, AST/ALT
level was >150 IU/L, or serum creatinine level was >1.4 mg/dL,
initiation of the next treatment cycle was postponed until recovery
of these data. If, during a treatment cycle, a patient showed a
leukocyte count of <2,000/mm3, platelet count of <70,000/mm3,
diarrhea >grade 1, mucositis in the oral cavity >grade 2, or rash
>grade 2, gemcitabine was not given on day 8 and S-1
administration was suspended. In patients who developed grade 4
leukopenia or neutropenia, febrile neutropenia or infection with
grade 3 leukopenia or neutropenia, grade 4 thrombocytopenia or
grade 3 thrombocytopenia requiring transfusion, or grade 3 rash, the
dose of gemcitabine was reduced to 800 mg/m2. In patients who
showed grade 4 leukopenia or neutropenia, febrile neutropenia or
infection with grade 3 leukopenia or neutropenia, grade 4
thrombocytopenia or grade 3 thrombocytopenia requiring
transfusion, a serum creatinine level ≥1.5 mg/dL, diarrhea ≥grade
3, mucositis in the oral cavity ≥grade 3, or rash ≥grade 3, the dose
of S-1 was reduced by 20 mg/day in the subsequent cycle.
Assessment of response and toxicity. Physical examination,
complete blood cell counts, serum chemistries and urinalysis were
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Table I. Patient characteristics (n=38).
Characteristics
Male                                                                           19 (50%)
Female                                                                       19 (50%)
Age (years)                                                                        
   Median age (range)                                              66 (44-81)
ECOG performance status                                               
   0                                                                              31 (82%)
   1                                                                               6 (16%)
   2                                                                                1 (2%)
Location of the primary tumor                                        
   Intrahepatic bile duct                                             12 (37%)
   Extrahepatic bile duct                                            14 (31%)
   Gallbladder                                                              9 (24%)
   Ampulla of Vater                                                     3 (8%)
   Prior chemotherapy                                                7 (18%)
   Adjuvant chemotherapy (S-1: GEM)                     6 (5:1)
   First-line chemotherapy (S-1)                                      1
ECOG, Eastern Cooperative Oncology Group.
performed at the baseline and at least twice every 3 weeks after
the start of treatment. Dynamic CT or MRI was performed to
evaluate the response at 4- to 6-week intervals after the start of
treatment. Computed tomography or MRI was performed by
obtaining contiguous transverse sections using the helical scanning
method, at a section thickness of 5 mm. Tumor response was
assessed using the Response Evaluation Criteria in Solid Tumors.
Objective responses were confirmed by a second evaluation
performed at least 4 weeks later. Toxicity was graded according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0. 
Study design. The primary endpoint of this study was the overall
response rate and the secondary endpoints were the
frequency/severity of adverse events, OS, and PFS. The threshold
response rate was defined as 17.5%, and the expected response rate
was set as 35%. A sample size of 40 would ensure that there was
80% statistical power at a one-sided significance level of 5%. The
accrual period was set at 2 years and the follow-up period at 1 year. 
Statistical analysis. Progression-free survival was calculated from
the first day of treatment until the appearance of evidence of tumor
progression, clinical progression, or death due to any cause. Overall
survival was calculated from the first day of treatment until death
due to any cause. Survival data were analyzed using the Kaplan-
Meier method. The tumor response, treatment toxicity, and survival
were evaluated based on intention-to-treat analyses. 
Results
Patient characteristics. A total of 40 patients were enrolled
between August 2008 and November 2011. Two patients
were excluded because of rapid clinical deterioration before
the first administration of the anticancer chemotherapy. The
patient characteristics are listed in Table I. There were 19
men and 19 women, with a median age of 66 years
(range=44-81 years). The PS was 0 and 1 in 30 and 7
patients, respectively. Seven patients had a previous history
of receiving first-line or adjuvant chemotherapy after
surgery. One patient had received S-1 treatment as first-line
chemotherapy. Of the six patients who had received prior
adjuvant chemotherapy, five patients received S-1 treatment
and one patient received gemcitabine alone.
Treatment. A total of 257 cycles of GS therapy were
administered, with a median of 5 cycles per patient (range,
1 to 27 cycles). Two patients were excluded because of rapid
clinical deterioration before the first administration of anti-
cancer treatment. In all the 38 enrolled patients, gemcitabine
was administered at 100% of the initially planned dose and
S-1 was administered at the dose of 80 mg/m2 in 10 patients
and at the dose of 100 mg/m2 in 24 patients. 
Of the 38 patients in whom the treatment was discontinued,
twenty-six (68.4%) showed disease progression and 2 (2.6%)
refused further continuation of the treatment because of adverse
events such as gastric ulcer and mucositis. Treatment was
discontinued because of adverse events in six (15.8%) patients,
including interstitial pneumonia in three patients, one with ileus
diarrhea and one with anorexia. One treatment-related death due
to interstitial pneumonia occurred. Two patients were lost to
follow-up because of moving to other hospitals or moving from
their houses. In one patient, the treatment was discontinued
based on the attending physician’s advice after patient was
confirmed to show a complete pathological response. 
After the GS treatment was discontinued, twenty-two
patients received second-line treatment, including systemic
chemotherapy with fixed dose-rate infusion of gemcitabine
with oral fluorinated pyrimidine compound S-1 (FGS
therapy) in six patients, gemcitabine in four patients, S-1 in
three patients, gemcitabine plus oxaliplatin (GEMOX
therapy) in three patients and a clinical trial treatment in one
patient; three patients underwent surgery. The remaining two
patients received only best supportive care.
Efficacy. One patient showed complete response (CR), while
five patients showed partial responses (PRs), representing an
overall objective response rate of 15.8% (Table II). Stable
disease was observed in twenty patients (62.5%), with an
overall disease control rate of 68.4%. Of the seven patients
with a previous history of having received chemotherapy,
one showed PR, two showed SD, two showed PD and
disease was not evaluated in 1 patient. The median overall
survival time was 15.9 months (95% CI=8.9-23.0 months;
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Table II. Tumor response.
                                               All patients (n=38)       IHCC patients (n=13)      EHCC patients (n=12)     GBC patients (n=10)     AVC patients (n=3)
Complete response                         1 (2.6%)                                0                                   1 (8.3%)                                0                                    0
Partial response                             5 (13.2%)                               0                                   1 (8.3%)                           4 (40%)                              0
Stable disease                               20 (52.6%)                       9 (69.2%)                           6 (50.0%)                          4 (40%)                       1 (33.3%)
Progressive disease                       6 (15.8%)                        3 (23.1%)                           2 (16.7%)                               0                             1 (33.3%)
Not evaluable                                6 (15.8%)                         1 (7.7%)                            2 (16.7%)                          2 (20%)                       1 (33.3%)
Objective response rate                   15.8%                                  0                                     16.7%                              40.0%                                0
Disease control rate                         68.4%                              69.2%                                66.7%                              40.0%                            33.3%
IHCC, Intrahepatic cholangiocarcinoma; EHCC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer; AVC, ampulla of Vater cancer.
Figure 1) and the median time-to-progression was 5.8
months (95% CI, 3.1-8.5 months; Figure 2). 
Safety. Table III shows the treatment-related adverse events.
Grade 3 or 4 toxicities were observed in 15 of the 40 patients
(38%). The major toxicities in Grade 3 or 4 patients were
leukopenia (31.6%, 12/38), neutropenia (36.8%, 14/38),
anemia (2.6%, 1/38), ALT elevation (2.6%, 1/38), AST
elevation (2.6%, 1/38), nausea/vomiting (2.6%, 1/38),
diarrhea (2.6%, 1/38) and interstitial pneumonia (2.6%,
1/38). The reported serious adverse events were grade 3
diarrhea and ileus, in addition to one case of treatment-
related death caused by interstitial pneumonia. There were
no cases of febrile neutropenia.
Discussion
This multicenter phase II study was conducted to evaluate
preliminary the efficacy and safety of GS therapy in patients
with unresectable biliary tract cancer, not only as first-line,
but also as second-line treatment. The primary endpoint was
the objective response rate, with the threshold response rate
defined as 17.5% and expected response rate set at 35% in
this study. The overall response rate was 15.8%, therefore,
the primary endpoint was not met in this study. We speculate
the following as some of the reasons for the endpoint not
having been met; some patients had a previous history of
treatments and in some patients, the response could not be
evaluated as they moved to another hospital. However, the
median PFS (5.8 months) and OS (15.9 months) were
promising, being comparable to those reported from other
studies of GS therapy (12, 14).
GS therapy has been reported to be generally well-
tolerated in previous clinical trials for biliary tract cancer and
pancreatic cancer. In the current study, the most common
ANTICANCER RESEARCH 37: 909-914 (2017)
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Figure 1. Overall survival in 38 patients administered GS therapy. The
median overall survival period was 15.9 months.
Figure 2. Progression-free survival in 38 patients treated with GS
therapy. The median progression-free survival period was 5.8 months.
Table III. Treatment-related adverse events (n=38): worst grade
reported during the treatment period.
                                                            Grade (n)                         Grade 3/4
                                            1             2             3            4              n (%)
Hematological                                                                                 
Leukopenia                         8           10           11            1           12 (31.6)
Neutropenia                        4             5           11            3           14 (36.8)
Anemia                             17             7             1            0             1 (2.6)
Thrombocytopenia           15             6             0            0              0
T-Bil elevation                   3             2             0            0              0
ALT elevation                  12             1             1            0             1 (2.6)
AST elevation                  17             0             1            0             1 (2.6)
Hypoalbuminemia            18             7             0            0              0
Non-hematological                                                                          
Mucositis                            6             3             0            0              0
Anorexia                             8             4             0            0              0
Nausea/vomiting                7             3             1            0             1 (2.6)
Diarrhea                              4             3             1            0             1 (2.6)
Interstitial pneumonia        2             0             1            0             1 (2.6)
Dyspnea                              1             0             0            0              0
Abdominal pain                  1             0             0            0              0
Rash                                    5             3             0            0              0
Fever                                   1             0             0            0              0
Alopecia                              7             0             0            0              0
Malaise                               7             1             0            0              0
Duodenal ulcer                   0             1             0            0              0
Pigmentation                       6             0             0            0              0
toxicities were neutropenia and leukopenia; grade 3/4
neutropenia and leukopenia developed in 36.8% and 31.6 of
patients, respectively. However, there was no patients with
febrile neutropenia. As for non-hematological toxicities,
grade 3 AST and ALT elevation was observed in one patient
(2.6%), and grade 3 nausea/vomiting, diarrhea, and
interstitial pneumonitis were observed in one patient (2.6%).
There was one treatment-related death due to interstitial
pneumonia. These safety profiles are comparable with those
reported from a previous randomized phase II study
conducted to compare the safety/efficacy of GS therapy and
S-1 alone (JCOG0805); in this aforementioned study,
however, febrile neutropenia was observed in 20% of cases
and there were two treatment-related deaths caused by
interstitial pneumonitis and myocardial infarction,
respectively. Interstitial pneumonitis was also observed in the
current study, therefore, close attention should be paid for
the development of early symptoms such as dry cough,
dyspnea and persistent fever.
Biliary tract cancer is generally recognized as a relatively
rare disease compared to other gastrointestinal cancers, such
as gastric and colorectal cancers. Although GC therapy is
currently recognized as the standard treatment for patients
with unresectable biliary tract cancer based on results of the
ABC-02 trial, few large clinical trials have been conducted
for patients with biliary tract cancer. In Japan, S-1 is
approved for the treatment of biliary tract cancer, based on
the results of a small phase II study of S-1 alone (15, 16),
and it is necessary to conduct further clinical trials to
confirm the efficacy and safety. A randomized phase II
study (JCOG0805) was conducted to compare the
efficacy/safety of GS therapy with that of S-1 monotherapy
and GS therapy was found to show more promising activity
compared to S-1 alone; the response rates were 36.4% in the
GS arm and 17.4% in the S-1 arm, and the median OS
durations were 12.5 months in the GS arm and 9.0 months
in S-1 arm. As a result, GS therapy is now considered as a
valid treatment alternative for biliary tract cancer to GC
therapy, because GS therapy is associated with a lower
incidence of gastrointestinal toxicities such as
nausea/vomiting and anorexia than GC therapy and the
venous infusion time is much shorter in GS therapy than in
GC therapy. Therefore, a non-inferiority phase III trial
between GC therapy and GS therapy (JCOG1113) is
currently ongoing (UMIN000010667). Furthermore, a triplet
regimen consisting of gemcitabine, a platinum agent and a
fluoropyrimidine has also been investigated. A phase II
study of gemcitabine plus cisplatin plus fluorouracil, which
was a relatively small study conducted in 21 patients,
showed a response rate of 33.3% and median OS of 18.8
months (17). A phase II study of gemcitabine plus cisplatin
plus S-1 (GCS therapy) also showed promising results, with
a response rate of 24% and median OS of 16.2 months (18).
As a consequence, a phase III trial comparing GCS therapy
with GC therapy is currently ongoing (UMIN000014371).
Although GC therapy is established as the first-line
treatment for biliary tract cancer, most patients develop
disease progression. In order to improve the survival,
effective second-line chemotherapy needs to be developed.
The impact of second-line therapy after gemcitabine-based
chemotherapy was assessed in the ABC-02 and BT-22
studies (19). In the ABC-02 trial conducted in the U.K., only
17% of the patients received further chemotherapy, mostly
5-FU based chemotherapy. On the other hand, more than
70% of the patients received post-study chemotherapy in the
BT-22 study conducted in Japan; more than 60% of the
patients were treated with S-1 as the second-line therapy. In
spite of the difference in the rate of application of second-
line therapy, the overall survival in the two studies was quite
similar. Furthermore, the phase II study of S-1 as failed to
demonstrate promising activity of the drug as second-line
treatment, with a response rate of 7.5%, median PFS of 2.5
months, and median OS of 6.8 months (20). So far, therefore,
the impact of second-line therapy remains unclear in patients
with gemcitabine-refractory biliary tract cancer. In this study,
we found that GS therapy may be indicated in patients with
a previous history of chemotherapy. In this study, seven
patients who had a previous history of chemotherapy were
included; even among these patients, one showed PR, and
two showed SD.
This study had several limitations. First of all, only a
small number of patients were included. The purpose of this
study is to preliminarily explore the efficacy and safety of
GS therapy for unresectable biliary tract cancer. Therefore,
we evaluated the response rate and safety profile in a small
number of patients. Secondly, this study included not only
patients without a previous history of chemotherapy, but also
those with a previous history of chemotherapy. It was
designed to evaluate the efficacy of GS therapy as second-
line treatment. However, it seemed to be difficult to
accurately evaluate the response rate.
In conclusion, although the current phase II study of GS
therapy failed to meet the primary endpoint (that is, an
objective response rate of 17.5%), it demonstrated promising
activity for improving the survival in patients with
unresectable biliary tract cancer. GS therapy may also be
effective as second-line treatment after GC therapy.
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